Replimune smashes Oncolytic viral €26.8M series A financing round

Replimune is an Oxford (UK) biotech baby, having only been founded in April this year a spin-off of former US BioVex. Nonetheless, this hasn’t stopped its Series A finance round reaching up to €26.8M. Replimune’s focal research is in developing new immuno-oncology therapies using oncolytic viruses, inspired by BioVex-Amgen’s T-VEC success.

AMGEN BIOVEX LOGOReplimune was founded by Robert Coffin, who had developed his expertise in oncolytic virus therapies for cancer whilst working as CSO at BioVex, a US based immuno-oncology pharma. BioVex was eventually bought out by Amgen for their talimogene laherparepvec (T-VEC) therapy for 378M back in 2011. With therefore strong links to Cambridge (MA),  Replimune hopes to continue research along the same lines as Biovex’s success.

Amgen’s T-VEC is currently undergoing FDA review for the US market as the first oncolytic viral therapy to succeed in its phase III trials. Derived from an engineered herpes-simplex virus 1, T-VEC is injected directly into tumors in order to cause lysis of the cancer cells, whilst also stimulating a localized immune response by tumeric released GM-CSF cytokines.


The mechanism of action of talimogene laherparepvec – branded T-VEC (CC: CaptainVivacious)

Since the virus is engineered to not replicate in healthy somatic cells, T-VEC is therefore a potent dual-mechanistic immuno-therapy for cancers such as melanoma. It acutely attacks tumors whilst at the same time promoting a longer term immune response against relapse. Replimune therefore hopes to build on the success of T-VEC’s pioneering mechanism, in order to innovate novel immuno-oncology therapies using oncolytic viruses.

Action of Enadenotucirev (EnAd) Candidare from PsiOxus (Source: PsiOxus)

Action of Enadenotucirev (EnAd) Candidare from PsiOxus (Source: PsiOxus)

Replimune is not the only biotech to have this idea however, with Austrian ViralTherapeutics raising €3.6M for its pre-clinical oncolytic candidate in June. This series A fundraising total is miniscule when compared to Replimune’s equivalent, but this could be an indication of Coffin and T-VEC’s tenure in VC immuno-oncology portfolio circles.

A more serious contender is PsiOxus Therapeutics from the UK, who has a strong financial backing from VC investors such as Imperial College London. Its enadenotucirev (EnAd) oncolytic viral vaccine has completed its phase I trial successfully and up to €34.7M in series C investment.

With this in mind, the real question is, is a history with BioVex and Amgen’s T-VEC enough to grant Replimune future success in the next generation of oncolytic viral therapies?

Let's Continue The Conversation

Feel free to send us comments about this article to and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.